DNA and MRNA Vaccines for Chronic Viral Infections and Cancer: Rationale, Mechanisms, and Progress

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Dec 11

PMID 36497356

Authors

Margaret A Liu

Affiliations

Soon will be listed here.

Abstract

Interest in the capabilities of nucleic acid vaccines, (DNA and mRNA vaccines) for both prophylactic and therapeutic uses have greatly increased following the successful deployment of two mRNA and, on a more limited scale, one DNA vaccine for COVID-19. In addition to targeting other pathogens for prophylactic vaccines, efforts are also being made towards using them for therapies for chronic infections and cancer. An examination of past and current successes for such therapies using other technologies with an emphasis on the immunological mechanisms will be provided followed by an assessment of the relevant characteristics of DNA and mRNA vaccines to predict their utility for therapies for chronic viral infections and cancer. Efforts and progress for these targets will be described.

References

Long A, Richard J, Hawley L, LaPatra S, Garver K . Transmission potential of infectious hematopoietic necrosis virus in APEX-IHN®-vaccinated Atlantic salmon. Dis Aquat Organ. 2017; 122(3):213-221. DOI: 10.3354/dao03076. View

Robert C . A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020; 11(1):3801. PMC: 7393098. DOI: 10.1038/s41467-020-17670-y. View

Ljungman P, Bermudez A, Logan A, Kharfan-Dabaja M, Chevallier P, Martino R . A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients. EClinicalMedicine. 2021; 33:100787. PMC: 8020145. DOI: 10.1016/j.eclinm.2021.100787. View

Toepfner N, von Meissner W, Strumann C, Drinka D, Stuppe D, Jorczyk M . Comparative Safety of the BNT162b2 Messenger RNA COVID-19 Vaccine vs Other Approved Vaccines in Children Younger Than 5 Years. JAMA Netw Open. 2022; 5(10):e2237140. PMC: 9579908. DOI: 10.1001/jamanetworkopen.2022.37140. View

Ventura C, Luis A, Soares C, Venuti A, Paolini F, Pereira L . The Effectiveness of Therapeutic Vaccines for the Treatment of Cervical Intraepithelial Neoplasia 3: A Systematic Review and Meta-Analysis. Vaccines (Basel). 2022; 10(9). PMC: 9500864. DOI: 10.3390/vaccines10091560. View

Okoye A, Picker L . CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure. Immunol Rev. 2013; 254(1):54-64. PMC: 3729334. DOI: 10.1111/imr.12066. View

Lorentzen C, Haanen J, Met O, Marie Svane I . Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol. 2022; 23(10):e450-e458. PMC: 9512276. DOI: 10.1016/S1470-2045(22)00372-2. View

Carlson R, Flickinger Jr J, Snook A . Talkin' Toxins: From Coley's to Modern Cancer Immunotherapy. Toxins (Basel). 2020; 12(4). PMC: 7232517. DOI: 10.3390/toxins12040241. View

Stevenson F, Zhu D, King C, Ashworth L, Kumar S, Thompsett A . A genetic approach to idiotypic vaccination for B cell lymphoma. Ann N Y Acad Sci. 1995; 772:212-26. DOI: 10.1111/j.1749-6632.1995.tb44747.x. View

10.

Ledgerwood J, Zephir K, Hu Z, Wei C, Chang L, Enama M . Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis. 2013; 208(3):418-22. PMC: 3699006. DOI: 10.1093/infdis/jit180. View

11.

Rosenberg S . IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014; 192(12):5451-8. PMC: 6293462. DOI: 10.4049/jimmunol.1490019. View

12.

Kohler G, Milstein C . Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975; 256(5517):495-7. DOI: 10.1038/256495a0. View

13.

Klein N, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson K . Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA. 2021; 326(14):1390-1399. PMC: 8511971. DOI: 10.1001/jama.2021.15072. View

14.

Malave Sanchez M, Saleeb P, Kottilil S, Mathur P . Oral Polio Vaccine to Protect Against COVID-19: Out of the Box Strategies?. Open Forum Infect Dis. 2021; 8(8):ofab367. PMC: 8344522. DOI: 10.1093/ofid/ofab367. View

15.

Borden E . Interferons α and β in cancer: therapeutic opportunities from new insights. Nat Rev Drug Discov. 2019; 18(3):219-234. DOI: 10.1038/s41573-018-0011-2. View

16.

Stevenson F, Zhu D, King C, Ashworth L, Kumar S, Hawkins R . Idiotypic DNA vaccines against B-cell lymphoma. Immunol Rev. 1995; 145:211-28. DOI: 10.1111/j.1600-065x.1995.tb00083.x. View

17.

Ye B, Liu X, Li X, Kong H, Tian L, Chen Y . T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. Cell Death Dis. 2015; 6:e1694. PMC: 4385920. DOI: 10.1038/cddis.2015.42. View

18.

Laupeze B, Del Giudice G, Doherty M, van der Most R . Vaccination as a preventative measure contributing to immune fitness. NPJ Vaccines. 2021; 6(1):93. PMC: 8316335. DOI: 10.1038/s41541-021-00354-z. View

19.

Syrengelas A, Chen T, Levy R . DNA immunization induces protective immunity against B-cell lymphoma. Nat Med. 1996; 2(9):1038-41. DOI: 10.1038/nm0996-1038. View

20.

Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View